Airway Therapeutics Secures $50M in Equity Financing to Advance Late-Stage Trials of Zelpultide Alfa for Bronchopulmonary Dysplasia in Preterm Infants
Executive Overview In a significant vote of confidence from its existing investor base, biopharmaceutical innovator Airway Therapeutics has successfully closed a $50 million equity financing round. This critical capital injection...
